Protalix BioTherapeutics
PLX
PLX
29 hedge funds and large institutions have $12.5M invested in Protalix BioTherapeutics in 2016 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
less ownership
Funds ownership: →
20% less capital invested
Capital invested by funds: $15.5M → $12.5M (-$3.03M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $12K
Holders
29
Holding in Top 10
–
Calls
–
Puts
$12K
Top Buyers
| 1 | +$44.4K | |
| 2 | +$23K | |
| 3 | +$23K | |
| 4 |
WS
Wedbush Securities
Los Angeles,
California
|
+$6.8K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$6K |
Top Sellers
| 1 | -$1.3M | |
| 2 | -$68K | |
| 3 | -$7K | |
| 4 |
SIM
Spark Investment Management
New York
|
-$6.73K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.62K |